Related Experiment Videos
The RIA for IGFBP-2 in man--a meagre catch?
1Department of Research and Internal Medicine, Kantonspital, University of Basel, Switzerland.
Growth Regulation
|March 1, 1993
Summary
Insulin-like growth factor-binding protein 2 (IGFBP-2) levels in human serum are age-dependent and increase with IGF-I treatment. Kidney function significantly impacts IGFBP-2 levels, and elevated levels are common in neoplastic diseases.
Area of Science:
- Endocrinology
- Biochemistry
- Nephrology
Background:
- Insulin-like growth factor-binding protein 2 (IGFBP-2) is a significant serum protein, also found in milk and cerebrospinal fluid.
- Serum IGFBP-2 concentrations exhibit age-dependent variations.
- Current evidence does not strongly support insulin's regulation of IGFBP-2 production or degradation.
Purpose of the Study:
- To elucidate the physiological regulation and clinical significance of IGFBP-2.
- To investigate the relationship between IGFBP-2, insulin, IGF-I, kidney function, and neoplastic diseases.
Main Methods:
- Analysis of serum IGFBP-2 concentrations in relation to age.
- Observation of IGFBP-2 levels following Insulin-like Growth Factor-I (IGF-I) treatment.
- Assessment of IGFBP-2 levels in patients with renal failure and post-renal transplantation.
- Evaluation of IGFBP-2 levels in individuals diagnosed with neoplastic diseases.
Main Results:
- Serum IGFBP-2 levels are age-dependent in humans.
- IGF-I treatment leads to an increase in serum IGFBP-2 concentration.
- IGFBP-2 is partially metabolized by the kidney, evidenced by its accumulation in renal failure patients and normalization post-transplantation.
- Elevated serum IGFBP-2 levels are frequently observed in patients with neoplastic diseases.
Conclusions:
- Serum IGFBP-2 levels are influenced by age, IGF-I treatment, and kidney function.
- Renal metabolism plays a role in IGFBP-2 clearance.
- Elevated IGFBP-2 may serve as a potential biomarker in neoplastic diseases.